Overview

A Study of Lasmiditan and Propranolol in Healthy Participants

Status:
Completed
Trial end date:
2017-11-22
Target enrollment:
Participant gender:
Summary
This study will assess the effects on heart rate and blood pressure when a single dose of lasmiditan is administered with a daily dose of propranolol. This study will also measure how much lasmiditan gets into the bloodstream after taking lasmiditan alone and after taking it together with propranolol. The study will also look at how well both drugs are tolerated. Information about any side effects that may occur will be collected. This study will last approximately 45 days including screening. This study will require 13 days/12 nights in a Clinical Research Unit (CRU) followed by 1 follow-up appointment approximately 7 days after the last dose. Screening is required within 28 days prior to the start of the study. This study is for research purposes only and is not intended to treat any medical condition.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Lasmiditan
Propranolol